Skip to content
DataLookout
Menu

NCT07916324

Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Difference Between Hands in Change From Baseline in Modified Hand Mobility in Scleroderma (mHAMIS) Score
Timeframe: Baseline and Months 1, 2, 3, and 6

Secondary (4)

Difference Between Hands in Change From Baseline in Regional Modified Rodnan Skin Score (mRSS)
Difference Between Hands in Change From Baseline in Finger-to-Palm Distance
Patient-Reported Pain Score in the Hyaluronidase-Treated Hand
Number of Participants With Treatment-Related Adverse Events

Arms and interventions

Arm Title: Left Hand Hyaluronidase, Right Hand ControlExperimental

Participants assigned to this arm will receive intradermal hyaluronidase injections in the left hand, while the right hand serves as an untreated control. Up to four treatment sessions will be administered at approximately monthly intervals. Both hands will undergo standardized assessments throughout the study.

Right Hand Hyaluronidase, Left Hand ControlExperimental

Participants assigned to this arm will receive intradermal hyaluronidase injections in the right hand, while the left hand serves as an untreated control. Up to four treatment sessions will be administered at approximately monthly intervals. Both hands will undergo standardized assessments throughout the study.

Drugs: hyaluronidase

Sites

1 site in 1 country

  • Stanford UniversityStanford, California, United States